前往化源商城

35457-80-8

35457-80-8结构式
35457-80-8结构式
  • 常用中文名:麦迪霉素
  • 常用英文名:midecamycin
  • CAS号:35457-80-8
  • 分子式:C41H67NO15
  • 分子量:813.968
  • 相关类别: 原料药 抗生素类药物 大环内酯类药
  • 发布时间:2018-02-06 08:00:00
  • 更新时间:2026-07-01 12:28:05
  • Midecamycin 是一种乙酰氧基取代的大环内酯类抗生素,可针对革兰氏阳性和阴性菌。

化源商城直购

中文名 麦迪霉素
英文名 Midecamycin
中文别名 麦迪霉素 标准品
MIDECAMYCIN 麦迪霉素
抗生素 SF-837
麦迪加霉素
(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-4-(二甲基氨基)-3-羟基-5-(((2S,4R,5S,6S)-4-羟基-4,6-二甲基
麦迪霉素
(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[[(2S,3R,4R,5S,6R)-4-(二甲氨基)-3-羟基-5-[[(2S,4R,5S,6S)-4-羟基-4,6-二甲基-5-(丙酰氧基)四氢-2H-吡喃-2-基]氧基]-6-甲基四氢-2H-吡喃-2-基]氧基]-10-羟基-5-甲氧基-9,16-二甲基-2-氧代-7-(2-氧代乙基)氧杂环十六烷-11,13-二烯-4-基丙酸酯
M860729,麦迪霉素
(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-4-(二甲基氨基)-3-羟基-5-(((2S,4R,5S,6S)-4-羟基-4,6-二甲基-5-(丙酰氧基)四氢-2H-吡喃-2-基)氧基)-6-甲基四氢-2H-吡喃-2-基)氧基)-10-羟基-5-甲氧基-9,16-二甲基-2-氧代-7-(2-氧乙基)氧杂环十六烷基-11,13-二烯基-4-丙酸酯
麦迪霉素对照品
麦地霉素
麦迪霉素(定性)
麦迪霉素,10 MM DMSO 溶液
英文别名 antibioticsf837a1
LeucoMycin V 3,4B-Dipropanoate
MFCD00070321
Aboren
Macropen
MIDECAMYCIN
Espinomycin A
leucomycinv,3,4(supb)-dipropanoate
Antibiotic YL 704B1
(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-4-(Dimethylamino)-3-hydroxy-5-(((2S,4R,5S,6S)-4-hydroxy-4,6-dimethyl-5-(propionyloxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-ox
Medecamycin A1
platenomycinb1
espinomycina
SF 837A1
Midecamycin, 10 mM in DMSO
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-4-(dimethylamino)-5-hydroxy-6-{[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-4-(propanoyloxy)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl propanoate
MIDECAMYCINE
Rubimycin
(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-4-(Dimethylamino)-3-hydroxy-5-(((2S,4R,5S,6S)-4-hydroxy-4,6-dimethyl-5-(propionyloxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl propionate
Madecacine
Medemycin A1
Leucomycin V 3,4B-Dipropanoate
Platenomycin B1
mydecamycin
Antibiotic SF 837
YL 704B1
Mydecamycin
Leucomycin V 3,4''-dipropionate
(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-{[(2S,3R,4R,5S,6R)-4-(Dimethylamino)-3-hydroxy-5-{[(2S,4R,5S,6S)-4-hydroxy-4,6-dimethyl-5-(propionyloxy)tetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl propanoate (non-preferred name)
Mydecamycin A1
midecamycina(sub1)
Turimycin P3
medemycin
Leucomycin V 3,4B-dipropionate
Oxacyclohexadecane, leucomycin V deriv
Normicina
(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-{[(2S,3R,4R,5S,6R)-4-(Dimethylamino)-3-hydroxy-5-{[(2S,4R,5S,6S)-4-hydroxy-4,6-dimethyl-5-(propionyloxy)tetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl propanoate
Myoxam
turimycinp(sub3)
propanoic acid [(11Z,13E)-6-[[(2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-[[(2S,4R,5R,6R)-4-hydroxy-4,6-dimethyl-5-(1-oxopropoxy)-2-oxanyl]oxy]-6-methyl-2-oxanyl]oxy]-10-hydroxy-5-methoxy-9,16-dime
midecamycin from strtomyces*mycofaciens
MIDECAMYCIN //BP
sf837
antibioticyl704b1
antibioticsf837
Midecamycin A1
Macro-Dil
Medemycin
Leucomycin V, 3,4B-dipropanoate (9CI)
Momicin
MoMicine
Midecin
medecamycin
EINECS 252-578-0
MIDECAMYCIN FROM STRTOMYCES &
描述 Midecamycin 是一种乙酰氧基取代的大环内酯类抗生素,可针对革兰氏阳性和阴性菌。
相关类别
靶点

Antibacterial[1]

体外研究 Midecamycin在低于3.1μg/ mL的浓度下抑制大部分链球菌,葡萄球菌和嗜血杆菌和李斯特菌的菌株[1]。麦迪霉素是16元大环内酯。麦迪霉素是一种新的大环内酯类抗生素,由链霉菌(Streptomyces mycarofaciens)产生[2]。
参考文献

[1]. Neu HC. In vitro activity of midecamycin, a new macrolide antibiotic. Antimicrob Agents Chemother. 1983 Sep;24(3):443-4.

[2]. Cong L, et al. Cloning and characterization of genes encoded in dTDP-D-mycaminose biosynthetic pathway from amidecamycin-producing strain, Streptomyces mycarofaciens. Acta Biochim Biophys Sin (Shanghai). 2007 Mar;39(3):187-93.

密度 1.2±0.1 g/cm3
沸点 874.0±65.0 °C at 760 mmHg
熔点 155℃ -156℃
分子式 C41H67NO15
分子量 813.968
闪点 482.4±34.3 °C
精确质量 813.451050
PSA 206.05000
LogP 3.53
蒸汽压 0.0±0.6 mmHg at 25°C
折射率 1.536
储存条件

密封、在2 ºC -8 ºC下保存

稳定性

如果遵照规格使用和储存则不会分解,未有已知危险反应

计算化学

1、 疏水参数计算参考值(XlogP):2.6

2、 氢键供体数量:3

3、 氢键受体数量:16

4、 可旋转化学键数量:14

5、 拓扑分子极性表面积(TPSA):206

6、 重原子数量:57

7、 表面电荷:0

8、 复杂度:1360

9、 同位素原子数量:0

10、 确定原子立构中心数量:7

11、 不确定原子立构中心数量:9

12、 确定化学键立构中心数量:2

13、 不确定化学键立构中心数量:0

14、 共价键单元数量:1

更多

1. 性状:未确定

2. 密度(g/mL,25ºC):未确定

3. 相对蒸汽密度(g/mL,空气=1): 未确定

4. 熔点(ºC):未确定

5. 沸点(ºC):未确定

6. 沸点(ºC,0.04mm hg):未确定

7. 折射率:未确定

8. 闪点(°C):未确定

9. 比旋光度(ºC):未确定

10. 自燃点或引燃温度(ºC): 未确定

11. 蒸气压(kPa,20ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性:未确定

生态学数据:

对水是稍微有危害的不要让未稀释或大量的产品接触地下水、水道或者污水系统,若无政府许可,勿将材料排入周围环境。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
OH4730600
CHEMICAL NAME :
Leucomycin V, 3,4(sup B)-dipropanoate
CAS REGISTRY NUMBER :
35457-80-8
LAST UPDATED :
199806
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C41-H67-N-O15
MOLECULAR WEIGHT :
814.09

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9600 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,810,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
11300 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,1330,1995
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,1330,1995
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
5800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,810,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
910 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 21,711,1973
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 21,711,1973
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
85GDA2 "CRC Handbook of Antibiotic Compounds," Vols.1- , Berdy, J., Boca Raton, FL, CRC Press, 1980- Volume(issue)/page/year: 2,83,1980 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
18 gm/kg
SEX/DURATION :
female 10-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 25,187,1972
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
3 gm/kg
SEX/DURATION :
female 10-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - physical
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 25,187,1972
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
6 gm/kg
SEX/DURATION :
female 10-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 25,187,1972
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
3 gm/kg
SEX/DURATION :
female 8-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 25,193,1972

RTECS号 OH4730600
本网页内容来自不同专业数据源,如对内容有疑义,欢迎联系service1@chemsrc.com。